Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock

Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The dividend is payable on October 15, 2015 to holders of record of Series B stock at the close of business on October 1, 2015.

Such payment will cover the amount of all dividends accrued from July 1, 2015 through September 30, 2015.

SOURCE Alere Inc.

Posted in: Business / Finance

Tags: , ,

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Alere Inc.. (2015, September 01). Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock. News-Medical. Retrieved on August 24, 2019 from https://www.news-medical.net/news/20150901/Alere-announces-cash-dividend-of-24300-per-share-on-Series-B-Convertible-Perpetual-Preferred-Stock.aspx.

  • MLA

    Alere Inc.. "Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock". News-Medical. 24 August 2019. <https://www.news-medical.net/news/20150901/Alere-announces-cash-dividend-of-24300-per-share-on-Series-B-Convertible-Perpetual-Preferred-Stock.aspx>.

  • Chicago

    Alere Inc.. "Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock". News-Medical. https://www.news-medical.net/news/20150901/Alere-announces-cash-dividend-of-24300-per-share-on-Series-B-Convertible-Perpetual-Preferred-Stock.aspx. (accessed August 24, 2019).

  • Harvard

    Alere Inc.. 2015. Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock. News-Medical, viewed 24 August 2019, https://www.news-medical.net/news/20150901/Alere-announces-cash-dividend-of-24300-per-share-on-Series-B-Convertible-Perpetual-Preferred-Stock.aspx.

Suggested Reading

FDA grants CLIA waiver for Alere i Strep A test
Alere announces cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock
Combatting Antibiotic Resistance, the role of POC Diagnostics
Alere wins ABFT accreditation to deliver post-mortem, human performance toxicology testing services
Alere doubles commitment to support OAFLA in eliminating mother-to-child transmission of HIV and EID
Alere supports DTHF’s Tutu Teen Truck project to expand reach of infectious services for youth
Alere i RSV test receives FDA CLIA waiver for detection of RSV infection in children, adults
Alere reports net revenue of $666.9 million for fourth quarter 2014

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
(Logout)
Post

Data Integrity in the Pharmaceutical Industry

There have been clear statements from regulatory bodies that have increased the pressure on pharmaceutical companies to go electronic with their records and ensure a high level of data integrity in all areas of the pharmaceutical industry.

Data Integrity in the Pharmaceutical Industry

IT Faces the Digital Pathology Data Tsunami

Digital pathology is the viewing, analyzing, and managing of digitalized pathology slides with computer technology called whole slide imaging, or WSI, which generates a tremendous volume of data. A single whole slide image can be a gigabyte or larger in size.

IT Faces the Digital Pathology Data Tsunami

Latest News

Newsletters you may be interested in

See all Newsletters »
You might also like... ×
Alere announces two transactions to further strengthen its core business strategy